Heparin-induced thrombocytopenia: A review

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 8, 2006, Pages 803-809

  Girolami, Bruno ^a   Girolami, Antonio ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Heparin therapy; Heparin induced thrombocytopenia; Review

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DANAPAROID; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; THROMBIN INHIBITOR; THROMBOCYTE FACTOR 4;

ADRENAL HEMORRHAGE; AMNESIA; ANAPHYLAXIS; ANTIGEN DETECTION; ARTERY THROMBOSIS; AUTOIMMUNE THROMBOCYTOPENIA; BLEEDING; DIAGNOSTIC VALUE; DISEASE SEVERITY; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; INCIDENCE; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SKIN NECROSIS; SYSTEMATIC REVIEW; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; VEIN THROMBOSIS;

ANTICOAGULANTS; AUTOIMMUNE DISEASES; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; RISK FACTORS; SEX FACTORS; THROMBOCYTOPENIA;

EID: 33845631960     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-955463     Document Type: Review

References (53)

1. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:31lS-337S
2. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121:535-555
3. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003;163:2518-2524
4. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986;67:27-30
5. Greinacher A, Amiral J, Dummel V, et al. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994; 34:381-385
6. Chong BH. Heparin induced thrombocytopenia. Aust NZ J Med 1992;22:145-152
7. 6a. Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med 1993;305:221-225
8. Ganzer D, Gutezeit A, Mayer G, Greinecher A, Eichler P. Prevention of thromboembolism as a cause of thromboembolic complications. A study of the incidence of heparin-induced thrombocytopenia type II. Z Orthop Ihre Grenzgeb 1997;135:543-549
9. Mahlfeld K, Franke J, Schaeper O, Kayser R, Grasshoff H. Heparin-induced thrombocytopenia as a complication of postoperative prevention of thromboembolism with unfractionated heparin/low molecular weight heparin after hip and knee prosthesis implantation. Unfallchirurg 2002;105:327-331
10. Ganzer D, Gutezeit A, Mayer G. Potentials risks in drug prevention of thrombosis-low-molecular-weight heparin versus standard heparin. Z Orthop Ihre Grenzgeb 1999; 137:457-461
11. Marx A, Huhle G, Hoffmann U, et al. Heparin-induced thrombocytopenia after elective hip joint replacement with postoperative prevention of thromboembolism with low-molecular-weight heparin. Z Orthop Ihre Grenzgeb 1999; 137:536-539
12. Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703-1708
13. Calaitges JG, Liem TK, Spadone D, Nichols WK, Silver D. The role of heparin-associated antiplatelet antibodies in the outcome of arterial reconstruction. J Vasc Surg 1999;29:779-785
14. Lindhoff-Last E, Eichler P, Stein M, et al. A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery. Thromb Res 2000;97:387-393
15. Kappers-Klunne MC, Boon DM, Hop WC, et al. Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseases. Br J Haematol 1997;96:442-446
16. Lozano M, Perez S, Cid J, et al. Is the incidence of heparin induced thrombocytopenia the same everywhere? The case of Spain. Thromb Haemost 2001(suppl); XVIII Congress ISTH (abst P2718)
17. Lindhoff-Last E, Nakov R, Misselwitz F, Breddin HK, Bauersachs R. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. Br J Haematol 2002;118:1137-1142
18. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003;101:2955-2959
19. Prandoni P, Siragusa S, Girolami B, Fabris F; BELZONI Investigators Group. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 2005;106:3049-3054
20. Visentin GP, Ford SE, Scott JP, Aster LH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994;93:81-88
21. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68:95-96
22. Kelton JG, Smith JW, Warkentin TE, et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994;83:3232-3239
23. Rauova L, Poncz M, McKenzie SE, et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005;105:131-138
24. Greinacher A, Alban S, Kummel V, et al. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 1995;74:886-892
25. Amiral J, Meyer D. Heparin-dependent antigens in heparin-induced antibodies. In: Warketin TE, Greinecher A, eds. Heparin-induced Thrombocytopenia. 3rd ed. New York, NY: Marcel Dekker; 2004:165-178
26. Ziporen L, Li ZQ, Park KS, et al. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 1998;92:3250-3259
27. Li ZQ, Liu W, Park KS, et al. Defining a second epitome for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood 2002;99:1230-1236
28. Suh JS, Malik MI, Aster RH, et al. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol 1997;54:196-201
29. Greinacher A, Potzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71:247-251
30. Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000;96:182-187
31. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286-1292
32. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135:502-506
33. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 1998;35:9-16
34. Blank M, Shoenfeld Y, Tavor S, et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 2002;14:121-129
35. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-507
36. Arthur CK, Grant SJB, Murray WK, et al. Heparin-associated acute adrenal insufficiency. Aust NZ J Med 1985;15:454-455
37. Warkentin TE, Hirte HW, Anderson DR, et al. Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am J Med 1994;97:489-491
38. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335
39. Greinacher A, Volpel H, Janssens U et al, for the HIT Investigators Group. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999;99:73-80
40. Greinacher A, Janssens U, Berg G et al, for the Heparin associated Thrombocytopenia Study (HAT) Investigators. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999;100:587-593
41. Eichler P, Lubenow N, Greinacher A. Results of the third prospective study of treatment with lepirudin in patients with heparin-induced thrombocytopenia (HAT). Blood 2002; 100(suppl 1):704a (abst)
42. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843
43. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163:1849-1856
44. Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocyto-penia. Thromb Haemost 2001;85:950-957
45. Warkentin TE. Danaparoid (Orgaran®) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: effects on in vivo thrombin and cross-linked fibrin generation, and evaluation of the clinical significance of in vitro cross-reactivity (XR) of danaparoid for HIT-IgG. Blood 1996;88(suppl 1):626a (abst)
46. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993;70:554-561
47. Magnani HN. Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia. Platelets 1997;8:74-81
48. Lubenow N, Eichler P, Lietz T, Farner B, Greinacher A. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 2004;104:3072-3077
49. Greinacher A, Volpel H, Janssens V, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation 1999;99:73-80
50. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163:1849-1856
51. Lewis BE. Argatroban in heparin-induced thrombocytopenia type II: clinical experience-trials and practice. Paper presented at: Symposium XIX ISTH Congress; July 12-18, 2003; Birmingham, UK
52. Gillis S, Merin G, Zahger D, et al. Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia. Br J Haematol 1997;98:657-659
53. Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001;85:950-957